Fig. 5: Findings in PD patients.
From: Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson’s Disease
A Example of 123I-FP-CIT (DaTSCANⓇ) SPECT imaging in a patient with PD who developed LID. R indicates the right side of the brain. The bar on the right side shows the color scale used for the uptake values (white 100%, on top, and black 0% on the bottom). In the six cuts, the asymmetrically reduced striatal uptake values are shown. B Differences in the putamen and caudate uptake values in dyskinetic (Dysk) and non-dyskinetic (Non-Dysk) patients (unpaired t-test Non-Dysk vs. Dysk DaTSCAN: Putamen, t = 5.863, df = 48, ***P < 0.001 and Caudate, t = 1.02, df = 48, P > 0.05). C Patients with and without LID share similar values of total-α-syn in serum (unpaired t-test Non-Dysk vs. Dysk, t = 0.271, df = 102, P > 0.05), and CSF (unpaired t-test Non-Dysk vs. Dysk, t = 0.306, df = 52, P > 0.05). D In Non-Dysk patients, cTBSc0 facilitates motor evoked potentials. cTBS150 given at 1 min after cTBSc0 reverses the potentiation following cTBSc0 by returning it to baseline level. Error bars refer to the standard error of the measurements (Two-way ANOVA of the time points after application of cTBS150: F3.93 = 24.74, P < 0.001). MEPs size was assessed after the end of TBS and every 5 min for 20 min after the end of TBS (respectively T1, T2, T3, T4 and T5). E In Dysk patients, cTBSc0 facilitates motor evoked potentials, while cTBS150 given at 1 min after cTBSc0 does not modify the facilitation produced by cTBSc0. Error bars refer to the standard error of the measurements (Two-way ANOVA of the time points after application of cTBS150: F3.93 = 0.006, P = 0.9). MEPs size was assessed after the end of TBS and every 5 min for 20 min after the end of TBS (respectively T1, T2, T3, T4 and T5). F The amount of depotentiation induced with cTBS150 given at 1 min after cTBSc0 (measured as percent change of normalized motor evoked potential -MEP- amplitudes between T1 and time points after cTBS150) inversely correlates to patients’ clinical dyskinesia scores (part III-UDysRS). Patients with more severe dyskinesia (higher scores) undergo lower depotentiation following cTBS150 than patients with less severe dyskinesia (lower scores).
